Skip to content

Effect of Unani formulation in low sperm count

Therapeutic evaluation of Unani formulation in Qillat-e-Mani: An Observationl study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/023723
Enrollment
30
Registered
2020-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

Intervention1: Unani formulation Majoon : Dose 6 gm Frequency once daily Route of administration orally Duration of therapy 60 days Control Intervention1: Not applicable: Not applicable

Sponsors

Luqman Unani Medical College Hospital Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male patients with oligospermia. 2.Patient having sperm count 3.Patient have ages above 21 years. 4.Informed volunteers giving written consent. 5.Patients who were willing for a follow-up and for semen examination. 6.No history of renal, hepatic disease or any other chronic illness.

Exclusion criteria

Exclusion criteria: 1)Patients of Azoospermia. 2)Patients with any genital infection and congenital genital anomaly.3)Patients suffering from Hypogonadism, Diabetes, any Neurological disorder, mentally retarded personâ??s varicocele. 4)Taking treatment for major psychiatric illness 5)History of previous medications and trauma leading to Oligozoospermia 6)Patient who do not report for follow up.

Design outcomes

Primary

MeasureTime frame
Change in sperm countTimepoint: At baseline and After 60 days from baseline

Secondary

MeasureTime frame
Change in Motility, Morphology, Semen volumeTimepoint: At baseline and After 60 days from baseline

Countries

India

Contacts

Public ContactDr Mohd khalid

Luqman Unani Medical College Hospital & Research Centre

dafedarabd@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026